AbbVie management will participate in a fireside chat on January 14, 2026 at 10:15 a.m. Central time as part of the 44th Annual J.P. Morgan Healthcare Conference. The live audio webcast will be accessible via the company’s Investor Relations site, and an archived edition will be available later that day. This marks AbbVie’s first public presentation since reporting a 9% year-over-year increase in 2025 revenues and underscores the company’s intention to update investors on its clinical pipeline and Allergan Aesthetics integration.

In 2025 AbbVie outperformed the healthcare sector, delivering total shareholder return of approximately 14% versus the sector’s 8%. Growth was driven by immunology and oncology franchises, with revenue rising 9% to $63.5 billion and adjusted EPS beating consensus by 5%. Looking ahead, the stock’s forward P/E multiple of 18x trades at a premium to the sector median of 15x, reflecting expectations for continued pipeline launches in neuroscience and eye care. However, potential price concessions from Most Favored Nation agreements could pressure gross margins by an estimated 200 basis points in 2026. A broader market rotation into cyclicals also poses near-term headwinds, though the company’s diversified portfolio and investment in R&D support a constructive long-term thesis.